Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01440231
Other study ID # EMR 700461-018
Secondary ID BB-IND 11,584
Status Withdrawn
Phase Phase 2
First received September 22, 2011
Last updated August 20, 2013
Start date February 2012
Est. completion date February 2014

Study information

Verified date August 2013
Source EMD Serono
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationSouth Africa: National Health Research Ethics Council
Study type Interventional

Clinical Trial Summary

Systemic lupus erythematosis (SLE) is an autoimmune disease, meaning that the body's immune system attacks its own organs and tissues. Within the immune system, B-cells and plasma cells make proteins called antibodies, which in autoimmune disease can bind to one's own tissues and are thus referred to as autoantibodies. Atacicept blocks 2 factors in the body, called BLyS and APRIL, which are important for the maintenance of B-cells and plasma cells, and thus the production of antibodies. This study will assess whether treatment with atacicept can reduce SLE disease activity. Atacicept is still an experimental drug, meaning that it is not available outside of a clinical trial, and that its potential benefits and risks have not been fully determined.

A total of 175 subjects are planned to be randomized (35 subjects per treatment arm) in a 1:1:1:1:1 ratio to receive either atacicept 5 mg, atacicept 25 mg, atacicept 75 mg, atacicept 115 mg or matching placebo, given subcutaneously once weekly for 24 weeks.

The primary objective of the trial is to evaluate the efficacy of atacicept compared to placebo in reducing SLE disease activity in subjects treated with standard of care (SoC) therapy and to investigate the dose-response relationship.

The secondary objectives of the trial are:

- To evaluate the effect of atacicept in reducing corticosteroid usage

- To evaluate the safety and tolerability profile of atacicept in subjects with SLE

- To confirm the PK and PD profiles of atacicept in SLE subjects

- To evaluate the changes in the Medical Outcomes Study Short Form General Health Survey [SF-36].


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 2014
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or female of =18 years of age

- Written informed consent

- Diagnosis of SLE satisfying at least 4 out of the 11 ACR criteria during the course of their illness

- Disease duration of at least 6 months

- SLEDAI-2K score = 6 at screening

- Positive test results for antinuclear antibody (ANA) (HEp-2 ANA =1:80) and/or anti-double-stranded deoxyribonucleic acid (dsDNA) (=30 IU/mL) at screening

- Negative serum pregnancy test and highly effective method of contraception for woman of childbearing potential.

Exclusion Criteria:

- Increase in dosing of corticosteroids within 2 weeks prior to screening

- Introduction of MMF within 3 months prior to TD1 or increase in dosing within 1 month before screening

- Change in dosing of immunosuppressants or corticosteroids during the screening period

- Serum IgG < 6g/L

- Estimated Glomerular Filtration Rate (GFR) <50 mL/min/1.73m²

- Urinary protein:creatinine ratio >2 mg/mg

- History of demyelinating disease

- Breastfeeding or pregnancy

- Legal or limited legal capacity

Additional exclusion criteria also apply

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Placebo
Matching placebo administered by subcutaneous injection, once weekly
Atacicept
Atacicept 5 mg administered by subcutaneous injection, once weekly
Atacicept
Atacicept 25 mg administered by subcutaneous injection, once weekly
Atacicept
Atacicept 75 mg administered by subcutaneous injection, once weekly
Atacicept
Atacicept 115 mg administered by subcutaneous injection, once weekly

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
EMD Serono

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline (trial day 1) in SLEDAI-2K Responder Index-50 (SRI-50) at week 24 of therapy The SRI-50 is a modification of the SLEDAI-2K, and allows detection of partial improvements (at least 50%) in SLE signs and symptoms assessed by SLEDAI-2K (Systemic Lupus Erythamtosus Disease Activity Index- 2000). 24 weeks No
Secondary Change from baseline to Week 24 in corticosteroid dose 24 weeks No
Secondary Change from baseline in serum Complement C3 levels at week 24 in subjects with low C3 at baseline 24 weeks No
Secondary Change from baseline in serum Complement C4 levels at week 24 in subjects with low C4 at baseline 24 weeks No
Secondary Change from baseline in anti-dsDNA antibodies (in subjects with anti dsDNA =30 IU/mL at baseline) and in ANA levels (in subjects with HEp-2 ANA =1:80 at baseline) at week 24 24 weeks No
Secondary Change from baseline in levels of total Ig and Ig classes (IgG, IgA, and IgM) at week 24 24 weekls No
Secondary The nature (preferred terms) and incidence of AEs Frequency tables summarizing the observed number of AEs by System Organ Class (SOC) and preferred term will be presented per regimen 24 weeks Yes
See also
  Status Clinical Trial Phase
Terminated NCT03843125 - A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE) Phase 3
Recruiting NCT05698173 - Systemic Lupus Erythematosus and Accelerated Aging N/A
Active, not recruiting NCT01649765 - Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy Phase 2
Recruiting NCT05704153 - Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A) N/A
Completed NCT05048238 - Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus Phase 1
Recruiting NCT06056778 - The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
Completed NCT04358302 - Individual Patient Exposure and Response in Pediatric Lupus N/A
Completed NCT03802578 - The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients N/A
Completed NCT02554019 - Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Phase 2
Recruiting NCT04835883 - Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients Phase 2
Terminated NCT02665364 - Phase IIb Study of IFN-K in Systemic Lupus Erythematosus Phase 2
Completed NCT00278538 - Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus Phase 2
Completed NCT00069342 - Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
Completed NCT03252587 - An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus Phase 2
Terminated NCT02066311 - Nelfinavir in Systemic Lupus Erythematosus Phase 2
Recruiting NCT01892748 - Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus. N/A
Terminated NCT01689025 - An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 1
Unknown status NCT01712529 - Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients N/A
Completed NCT01475149 - Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE) N/A
Completed NCT00962832 - A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus Phase 2